Intuitive Surgical, Inc. (ISRG)

In the past six months, Intuitive Surgical's stock (ISRG) has experienced significant positive movement, largely driven by strong financial performance and product advancements. The stock rose by 23.9% over the past month and 27.74% over the past six months as of October 14, 2025. In October 2025, Intuitive Surgical reported robust third-quarter results, exceeding Wall Street's revenue and earnings per share (EPS) expectations, leading to a significant stock surge. The company reported a 20% increase in worldwide procedures (da Vinci and Ion combined) compared to Q3 2024, with da Vinci procedures growing by 19% and Ion procedures by 52%, and placed 427 da Vinci surgical systems in Q3 2025, including 240 of the new da Vinci 5 systems. Following the strong Q3 results, Intuitive Surgical raised its full-year guidance for da Vinci procedure growth to 17%-17.5% and its pro forma gross margin range to 67%-67.5%. The gradual increase in placements and the CE Mark approval in Europe for the da Vinci 5 system in July 2025 have been positive drivers. Numerous Wall Street analysts have raised their price targets for ISRG, reflecting a generally positive sentiment. The company repurchased 4 million shares of its common stock for $1.92 billion in the third quarter of 2025. Over the past six months, Intuitive Surgical insiders have primarily sold shares, with 32 sales and no purchases, and members of Congress have also traded ISRG stock, with 3 purchases and 4 sales.

While specific seasonal fluctuations in demand for Intuitive Surgical's products and services are not explicitly detailed in the provided information, the company has demonstrated consistently strong and accelerating demand. Recent reports highlight robust growth in da Vinci and Ion procedure volumes, as well as increased system placements across quarters. In Q3 2025, worldwide procedures grew approximately 20% year-over-year, with da Vinci procedures up 19% and Ion procedures up 52%, and the company also saw a 12% increase in da Vinci system placements in Q3 2025 compared to the prior year, driven entirely by the da Vinci 5 system. This consistent growth in procedure volume and system adoption suggests a generally upward trend in demand, rather than pronounced seasonality tied to specific times of the year, and the company's guidance for continued procedure growth in 2025 further reinforces this trend.

Intuitive Surgical, Inc. (ISRG) is a leading American biotechnology company specializing in robotic-assisted minimally invasive surgery, operating within the Health Care sector, specifically in the Medical Appliances & Equipment and Medical Specialties industries. Its core business revolves around providing robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company's major products include the da Vinci Surgical System, which enables complex surgery using a minimally invasive approach, offering surgeons superior visualization, enhanced dexterity, greater precision, and ergonomic comfort. The da Vinci product line includes various models such as the da Vinci 5, da Vinci X, Xi, and SP (single-port) systems, along with specialized instruments, accessories, staplers, energy devices, and vision systems like Firefly Fluorescence imaging. The Ion Endoluminal System extends Intuitive's offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung using an ultra-thin, maneuverable catheter. The company also provides a range of instruments, disposable accessories, software (e.g., PlanPoint for biopsy planning, SimNow for surgical skills training), and services for its systems.

Headquartered in Sunnyvale, California, U.S., Intuitive Surgical distributes its products worldwide. As of September 30, 2025, the company had an installed base of 10,763 da Vinci surgical systems globally, an increase of 13% from the previous year, and the Ion endoluminal system's installed base grew to 954 systems, a 30% increase. Intuitive Surgical markets its products through direct sales organizations and distributors across North America, South America, Europe, Asia-Pacific, the Middle East, and Africa. The company also maintains regional offices in various countries, including Canada, Switzerland, Germany, the UK, France, Japan, South Korea, India, Taiwan, and China. In January 2025, Intuitive announced plans to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino by acquiring the da Vinci and Ion distribution businesses in these countries, with the transaction expected to close in 2026.

Intuitive Surgical maintains a strong brand reputation as a pioneer and global technology leader in robotic-assisted minimally invasive surgery. The company is often considered the "gold standard" in its field, with a dominant market position and a strong moat built on its first-mover advantage, regulatory scale, and high surgeon adoption. Analysts generally hold a positive view, highlighting its innovative contributions to healthcare and its ability to drive market conversion to robotics. However, the company's reputation faced challenges in 2021 when it was sued for alleged abuse of its monopolistic position, which led to a wave of similar class-action lawsuits, but the case, Rebotix v. Intuitive, was settled out of court in August 2022.

Intuitive Surgical's stock ownership is primarily held by institutional investors, who collectively own approximately 75% to 83.64% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Price T Rowe Associates Inc /md/, Fidelity Investments (FMR), JPMorgan Chase & Co, Geode Capital Management, Llc, and Capital World Investors. Individual ownership (retail investors and insiders) accounts for approximately 25% of the company, and insider trading activity in the past six months has shown more sales than purchases.